Abeona Therapeutics to Participate in the Cantor Fitzgerald Virtual Rare Orphan Disease Summit
Abeona Therapeutics (Nasdaq: ABEO) announced CEO Vish Seshadri's participation in a panel at the Cantor Fitzgerald Virtual Rare Disease Summit on March 30, 2022, at 4:00 p.m. ET. The discussion will focus on the evolving definition of cell therapy and its applications for rare diseases.
Abeona is known for its gene and cell therapies aimed at serious diseases, including Phase 3 development of EB-101 for epidermolysis bullosa, and Phase 1/2 therapies ABO-102 and ABO-101 for Sanfilippo syndrome.
- None.
- None.
NEW YORK and CLEVELAND, March 28, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that Vish Seshadri, Ph.D., Chief Executive Officer of Abeona Therapeutics, will participate in a panel discussion titled, “Cell Therapy: How the Definition has Expanded with Time, and the Potential Applications for Rare Diseases,” at the Cantor Fitzgerald Virtual Rare Disease Summit on Wednesday, March 30, 2022 at 4:00 p.m. ET.
Those interested in participating in the Cantor Fitzgerald Virtual Rare Orphan Disease Summit are encouraged to contact their Cantor Fitzgerald representative.
About Abeona Therapeutics
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene and cell therapies for serious diseases. Abeona’s clinical programs include EB-101, its investigational autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa in Phase 3 development, as well as ABO-102 and ABO-101, novel investigational AAV-based gene therapies for Sanfilippo syndrome types A and B (MPS IIIA and MPS IIIB), respectively, in Phase 1/2 development. The Company’s development portfolio also features AAV-based gene therapies for ophthalmic diseases with high unmet medical need. Abeona’s novel, next-generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. Abeona’s fully integrated gene and cell therapy cGMP manufacturing facility produces EB-101 for the pivotal Phase 3 VIITAL™ study and is capable of clinical and planned commercial production of AAV-based gene therapies. For more information, visit www.abeonatherapeutics.com.
Forward-Looking Statements
This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties. We have attempted to identify forward-looking statements by such terminology as “may,” “will,” “believe,” “estimate,” “expect,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances), which constitute and are intended to identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, numerous risks and uncertainties, including but not limited to the potential impacts of the COVID-19 pandemic on our business, operations, and financial condition, continued interest in our rare disease portfolio, our ability to enroll patients in clinical trials, the outcome of any future meetings with the U.S. Food and Drug Administration or other regulatory agencies, the impact of competition, the ability to secure licenses for any technology that may be necessary to commercialize our products, the ability to achieve or obtain necessary regulatory approvals, the impact of changes in the financial markets and global economic conditions, risks associated with data analysis and reporting, our ability to execute our operating plan and achieve important anticipated milestones, and other risks disclosed in the Company’s most recent Annual Report on Form 10-K and subsequent quarterly reports on Form 10-Q and other periodic reports filed with the Securities and Exchange Commission. The Company undertakes no obligation to revise the forward-looking statements or to update them to reflect events or circumstances occurring after the date of this press release, whether as a result of new information, future developments or otherwise, except as required by the federal securities laws.
FAQ
What will be discussed at the Cantor Fitzgerald Virtual Rare Disease Summit involving Abeona Therapeutics?
When is the Cantor Fitzgerald Virtual Rare Disease Summit where Abeona Therapeutics will participate?
What therapies is Abeona Therapeutics currently developing?
What is the significance of the panel discussion for Abeona Therapeutics?